DARE BIOSCIENCE INC. - COMMON STOCK

Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

05 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

31 May 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update

11 May 2023 08:00:03 By Nasdaq GlobeNewswire

Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023

04 May 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%

20 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany

19 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference

17 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

23 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Present at the 35th Annual Roth Conference

01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

22 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Participate in Three February Conferences

01 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

26 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

09 Jan 2023 08:00:02 By Nasdaq GlobeNewswire

Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea

12 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

15 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

14 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

10 Nov 2022 05:45:00 By Nasdaq GlobeNewswire